Shukra Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	220.58	95.75	185.37	44.07	7.51
Depreciation & Amortization	34.43	30.05	20.5	18.38	16.62
Other Operating Activities	44.84	-8.85	2.21	-4.5	0.8
Change in Accounts Receivable	-141.81	157.46	56.74	-227.86	23.47
Change in Inventory	-39.5	-76.39	8.42	7.97	-22.72
Change in Accounts Payable	8.49	19.95	-261.51	260.97	32.61
Change in Other Net Operating Assets	-87.72	-138.79	-63.7	-67.33	21.6
Operating Cash Flow	39.31	79.18	-51.97	31.7	79.89
Operating Cash Flow Growth	-50.35%	-	-	-60.32%	1386.79%
Capital Expenditures	-157.3	-27.43	-17.6	-44.91	-15.5
Investment in Securities	-	-	-	-	-0.09
Other Investing Activities	15.87	14.79	5.59	0.64	0.31
Investing Cash Flow	-141.43	-12.64	-12.01	-44.27	-15.28
Long-Term Debt Issued	0.8	4.56	-	6.42	-
Long-Term Debt Repaid	-	-	-11.12	-	-63.94
Net Debt Issued (Repaid)	0.8	4.56	-11.12	6.42	-63.94
Issuance of Common Stock	-	-	138.72	46.28	-
Common Dividends Paid	-4.38	-43.79	-0.7	-0.73	-
Other Financing Activities	44.28	-5.95	-2.85	-2.56	-2.81
Financing Cash Flow	40.7	-45.18	124.05	49.41	-66.75
Miscellaneous Cash Flow Adjustments	0	-	0	-	-
Net Cash Flow	-61.41	21.37	60.08	36.84	-2.15
Free Cash Flow	-117.99	51.75	-69.57	-13.22	64.39
Free Cash Flow Margin	-20.80%	15.88%	-9.33%	-2.22%	31.43%
Free Cash Flow Per Share	-0.27	0.12	-0.16	-0.20	1.03
Cash Interest Paid	9.64	5.95	2.85	2.56	2.81
Cash Income Tax Paid	16.22	37.62	6.25	2.5	4.37
Levered Free Cash Flow	-137.74	32.25	-123.17	-43.52	57.98
Unlevered Free Cash Flow	-130.91	35.51	-121.45	-41.92	59.74
Change in Working Capital	-260.54	-37.77	-260.05	-26.24	54.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.